Sign in Subscribe
COVID-19

COVID-19 Vaccine Immunogenicity Evaluation: Breakthrough Enzyme-Linked Immunosorbent Assay for Emerging Variants

Strategic Insights

— 1 min read

Researchers from Novavax Inc. have published a groundbreaking study on COVID-19 vaccine immunogenicity evaluation, introducing a novel enzyme-linked immunosorbent assay (ELISA) to assess antibody responses against emerging SARS-CoV-2 variants. The study highlights the importance of clinical immunogenicity biomarkers in addressing the growing threat of immune evasion posed by emerging variants. The ELISA assay, validated for precision, specificity, and linearity, provides a rapid and high-throughput method for evaluating vaccine immunogenicity and correlates of protection.

Key Takeaways:

  • The hACE2 assay showed significant correlation with anti-recombinant S immunoglobulin G levels and neutralizing antibody titers, demonstrating its utility in vaccine immunogenicity evaluation.
  • The ELISA assay is a rapid, high-throughput option for evaluating vaccine immunogenicity, providing valuable insights into immune evasion and correlates of protection against emerging COVID-19 variants.
  • The study highlights the importance of developing better clinical immunogenicity biomarkers to address the need for more effective vaccine responses against emerging variants.
  • Novavax Inc. funded the research, which was conducted by Urvashi Patel and a team of researchers, including Mingzhu Zhu, Shane Cloney-Clark, Edmond Massuda, and others.
  • The ELISA assay was adapted for variants, including Delta and Omicron BA.1/BA.5, with similar validation results, demonstrating its adaptability for emerging variants.

Statistics:

  • The hACE2 assay showed significant correlation with anti-recombinant S immunoglobulin G levels (R = 0.93, p < 0.001).
  • The ELISA assay demonstrated precision (CV < 10%) and specificity (100% sensitivity) for detecting antibodies against the SARS-CoV-2 spike protein.
  • The assay showed minimal interference from heme and lipid matrix effects, with samples stable for testing even with 8 freeze/thaws and up to 24 months in -80 °C storage.

Sources:

  • Microorganisms (Journal): Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation. Microorganisms, 2023,11(2). (Microorganisms - http://www.mdpi.com/journal/microorganisms)
  • MDPI AG (Publisher): Microorganisms (Journal)
  • https://doi-org.sdpl.idm.oclc.org/10.3390/microorganisms11020368 (Free version of the journal article)
  • NewsRx LLC (Citation): NewsRx. Research from Novavax Inc. Provides New Data on COVID-19 [Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity ...]. Vaccine Weekly. February 22, 2023; p 449.

Read more